These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 21131943

  • 21. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
    Paisley AN, Savage MW, Wiles PG.
    Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
    [Abstract] [Full Text] [Related]

  • 22. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.
    Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS, Thompson DM.
    Transplantation; 2007 Jan 15; 83(1):24-8. PubMed ID: 17220786
    [Abstract] [Full Text] [Related]

  • 23. Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.
    Son JP, Son MK, Jun SW, Kwak HH, Kang SH, Kang JS, Park YI.
    Pharmazie; 2013 Jan 15; 68(1):58-62. PubMed ID: 23444782
    [Abstract] [Full Text] [Related]

  • 24. Exenatide once weekly in type 2 diabetes mellitus.
    Bischoff LA, Jabbour SA, Miller JL.
    Expert Opin Pharmacother; 2011 Jun 15; 12(8):1297-1303. PubMed ID: 21548720
    [No Abstract] [Full Text] [Related]

  • 25. Effectiveness of the novel anti-diabetes medication exenatide in everyday practice: Comparison with clinical trials.
    Donekal S, Shomali ME.
    Diabetes Res Clin Pract; 2008 May 15; 80(2):e4-6. PubMed ID: 18314214
    [Abstract] [Full Text] [Related]

  • 26. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B.
    Int J Clin Pract; 2006 Dec 15; 60(12):1654-61. PubMed ID: 17109672
    [Abstract] [Full Text] [Related]

  • 27. Thermo-reversible injectable gel based on enzymatically-chopped low molecular weight methylcellulose for exenatide and FGF 21 delivery to treat types 1 and 2 diabetes.
    Kim JK, Yoo C, Cha YH, Kim YH.
    J Control Release; 2014 Nov 28; 194():316-22. PubMed ID: 25245775
    [Abstract] [Full Text] [Related]

  • 28. Time for clinically relevant comparative effectiveness studies in type 2 diabetes.
    Nathan DM.
    Ann Intern Med; 2011 Jan 18; 154(2):131-2. PubMed ID: 21135287
    [No Abstract] [Full Text] [Related]

  • 29. Eosinophil-rich granulomatous panniculitis caused by exenatide injection.
    Boysen NC, Stone MS.
    J Cutan Pathol; 2014 Jan 18; 41(1):63-5. PubMed ID: 24224897
    [No Abstract] [Full Text] [Related]

  • 30. Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients.
    Blaslov K, Zibar K, Bulum T, Duvnjak L.
    Clin Res Hepatol Gastroenterol; 2014 Jun 18; 38(3):e61-3. PubMed ID: 24315013
    [No Abstract] [Full Text] [Related]

  • 31. Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review.
    Olaywi M, Bhatia T, Anand S, Singhal S.
    Hepatobiliary Pancreat Dis Int; 2013 Dec 18; 12(6):584-8. PubMed ID: 24322742
    [Abstract] [Full Text] [Related]

  • 32. Hormone copycats.
    Gebel E.
    Diabetes Forecast; 2012 Jun 18; 65(6):36, 38-9. PubMed ID: 22737769
    [No Abstract] [Full Text] [Related]

  • 33. Long-term Efficacy and Safety of Exenatide Treatment.
    Chirapongsathorn S, Anthanont P.
    Mayo Clin Proc; 2015 Sep 18; 90(9):1304. PubMed ID: 26355405
    [No Abstract] [Full Text] [Related]

  • 34. In reply--Long-term Efficacy and Safety of Exenatide Treatment.
    Wysham CH.
    Mayo Clin Proc; 2015 Sep 18; 90(9):1304-5. PubMed ID: 26355404
    [No Abstract] [Full Text] [Related]

  • 35. New drug and dosage form.
    Am J Health Syst Pharm; 2005 Jun 01; 62(11):1122. PubMed ID: 15914871
    [No Abstract] [Full Text] [Related]

  • 36. Exenatide and pramlintide: new therapies for diabetes.
    Want LL, Ratner R.
    Int J Clin Pract; 2006 Dec 01; 60(12):1522-3. PubMed ID: 17109659
    [No Abstract] [Full Text] [Related]

  • 37. First in class. Two new diabetes drugs.
    Koredella T.
    Diabetes Forecast; 2005 Aug 01; 58(8):35-6. PubMed ID: 16124101
    [No Abstract] [Full Text] [Related]

  • 38. Exenatide-a potential role in treatment of HNF1-alpha MODY in obese patients?
    Ahluwalia R, Perkins K, Ewins D, Goenka N.
    Diabet Med; 2009 Aug 01; 26(8):834-5. PubMed ID: 19709161
    [No Abstract] [Full Text] [Related]

  • 39. Effect of exenatide on fat deposition and a metabolic profile in patients with metabolic syndrome.
    González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, Ramos-Zavala MG.
    Metab Syndr Relat Disord; 2011 Feb 01; 9(1):31-4. PubMed ID: 20874425
    [Abstract] [Full Text] [Related]

  • 40. [Lixisenatide (Lyxumia), subcutaneous].
    J Pharm Belg; 2014 Jun 01; (2):57-9. PubMed ID: 25055456
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.